Biomarker development in the precision medicine era: lung cancer as a case study

被引：389
|
作者：
Vargas, Ashley J. [1 ,2 ]
Harris, Curtis C. [1 ]
机构：
[1] NCI, Lab Human Carcinogenesis, Ctr Canc Res, Room 3068A,MSC 425,837 Convent Dr, Bethesda, MD 20892 USA
[2] NCI, Canc Prevent Div, Rockville, MD 20850 USA
来源：
NATURE REVIEWS CANCER | 2016年 / 16卷 / 08期
关键词：
C-REACTIVE PROTEIN; REPORTING RECOMMENDATIONS; GENE-EXPRESSION; INTERNATIONAL-ASSOCIATION; PROGNOSTIC CLASSIFIER; COMPANION DIAGNOSTICS; AFRICAN-AMERICANS; EGFR MUTATIONS; MESSENGER-RNA; NEVER SMOKERS;
D O I：
10.1038/nrc.2016.56
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Precision medicine relies on validated biomarkers with which to better classify patients by their probable disease risk, prognosis and/or response to treatment. Although affordable 'omics'-based technology has enabled faster identification of putative biomarkers, the validation of biomarkers is still stymied by low statistical power and poor reproducibility of results. This Review summarizes the successes and challenges of using different types of molecule as biomarkers, using lung cancer as a key illustrative example. Efforts at the national level of several countries to tie molecular measurement of samples to patient data via electronic medical records are the future of precision medicine research.
引用
收藏
页码：525 / 537
页数：13
相关论文
共 50 条
  • [1] Biomarker development in the precision medicine era: lung cancer as a case study
    Ashley J. Vargas
    Curtis C. Harris
    Nature Reviews Cancer, 2016, 16 : 525 - 537
  • [2] Lung Cancer in the Era of Precision Medicine
    Politi, Katerina
    Herbst, Roy S.
    CLINICAL CANCER RESEARCH, 2015, 21 (10) : 2213 - 2220
  • [3] Time to Rethink the Role of Clinical Pathways in the Era of Precision Medicine: A Lung Cancer Case Study
    Schleicher, Stephen M.
    Chaudhry, Basit
    Dickson, Natalie R.
    Aviki, Emeline
    Arrowsmith, Edward
    Parikh, Ravi B.
    Yue, Andrew T.
    Connor, Nora
    Schwartzberg, Lee
    Lyss, Aaron J.
    JCO ONCOLOGY PRACTICE, 2021, 17 (07) : 379 - +
  • [4] Considerations of Biomarker Application for Cancer Continuum in the Era of Precision Medicine
    Hung, Rayjean J.
    Moez, Elham Khodayari
    Kim, Shana J.
    Budhathoki, Sanjeev
    Brooks, Jennifer D.
    CURRENT EPIDEMIOLOGY REPORTS, 2022, 9 (03) : 200 - 211
  • [5] Considerations of Biomarker Application for Cancer Continuum in the Era of Precision Medicine
    Rayjean J. Hung
    Elham Khodayari Moez
    Shana J. Kim
    Sanjeev Budhathoki
    Jennifer D. Brooks
    Current Epidemiology Reports, 2022, 9 : 200 - 211
  • [6] Molecular testing in lung cancer in the era of precision medicine
    Popper, Helmut H.
    Ryska, Ales
    Timar, Jozsef
    Olszewski, Wlodzimierz
    TRANSLATIONAL LUNG CANCER RESEARCH, 2014, 3 (05) : 291 - 300
  • [7] EGFR mutations and lung cancer: the era of precision medicine in oncology
    Sekerus, V.
    Andrijevic, L.
    Lazin, S.
    Potic, M.
    Vuckovic, D.
    Lovrenski, A.
    Tegeltija, D.
    Andrijevic, I.
    FEBS OPEN BIO, 2022, 12 : 87 - 88
  • [8] Small cell lung cancer enters the era of precision medicine
    Frese, Kristopher K.
    Simpson, Kathryn L.
    Dive, Caroline
    CANCER CELL, 2021, 39 (03) : 297 - 299
  • [9] Optimized biomarker evaluation and molecular testing in the era of breast cancer precision medicine
    Hicks, David G.
    Turner, Bradley M.
    BIOTECHNIC & HISTOCHEMISTRY, 2024,
  • [10] Biomarker Landscape in Multicenter China Lung Cancer Precision Medicine Registry
    Wu, J.
    Ji, W.
    Fu, N.
    Rong, H.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S426 - S427
12345